#United States #Kessler Topaz #Settlement #Tacoma #CytoDyn

Overview of the CytoDyn, Inc. Settlement

On July 22, 2026, Kessler Topaz Meltzer & Check, LLP announced a proposed class action settlement concerning the common stock of CytoDyn, Inc. This action affects those who purchased shares between March 27, 2020, and March 30, 2022. The legal developments are significant for shareholders looking to understand their rights and any potential financial recoveries.

The Class Action Details

The lawsuit has been provisionally certified as a class action by the United States District Court for the Western District of Washington. This certification pertains to individuals and entities who bought or acquired CytoDyn's common stock during the defined period and were negatively impacted as a result.

Lead plaintiff Brian Joe Courter, along with Courter and Sons LLC, initiated the action against CytoDyn Inc. and its executives: Nader Z. Pourhassan, Michael Mulholland, and Scott A. Kelly. These parties are collectively being referred to as the 'Defendants'.

The case, designated as No. 321-cv-05190-BHS, brings to light the complexities faced by investors as they navigate this situation. With so many involved, understanding the implications of this settlement is crucial.

Financial Terms of the Settlement

Proposed compensation for the affected parties includes 49 million shares of CytoDyn common stock and $500,000 in cash. If the court approves the settlement – which is expected to resolve all claims in this action – it will be a notable milestone for investors who have been awaiting clarity and remediation regarding their losses.

Settlement Hearing Information

A hearing to discuss the settlement is scheduled for November 2, 2026, at 1:30 p.m. This session will be presided over by the Honorable Benjamin H. Settle in Tacoma, Washington, either in person or via teleconference or video call. During this hearing, the court will evaluate whether the proposed terms are fair and reasonable, alongside other pertinent issues regarding the class action status and the appropriateness of the appointed lead counsel.

Important Deadlines

Affected parties should note several key dates:

• - Claim Form Submission Deadline: Investors must submit a Claim Form to be postmarked or filed online by September 21, 2026, to participate in the settlement.
• - Exclusion Request Deadline: Those wishing to opt out must submit their request by October 12, 2026.
• - Objection Deadline: Any objections to the settlement, allocation plan, or legal fees must also be filed by October 12, 2026.

Additional Information and Resources

Important documents, like the Stipulation and Notice relating to the settlement, can be accessed online at CytoDyn Securities Settlement. For further inquiries, interested parties can contact the Claims Administrator or lead counsel listed in the notice. It’s imperative for potential claimants to stay informed and carefully review these resources to understand their rights and options in this ongoing legal situation.

The outcomes of this case could influence widespread perceptions of corporate governance in the biotech sector and highlight the legal support available to investors facing challenges in stock acquisition scenarios. This settlement could set a precedent for similar future cases involving shareholders and corporate transparency.

Stay tuned for updates as the hearing date approaches, and make sure all necessary actions are taken to ensure eligibility for any compensatory measures stemming from this settlement.